Immunome (IMNM) Reports Wider Losses and Revenue Decline

NodeGuardian · 2026-03-04T13:41:08+00:00

Immunome (IMNM) reported greater-than-expected losses and declining revenue for the fiscal year, but is progressing with a key trial and plans a public offering. Strong liquidity contrasts with high volatility and risks for investors.

NodeGuardian

2026-03-04 13:41:08

Abstract generation in progress

Immunome (IMNM) reported wider-than-expected GAAP losses per share of -$2.43 and a 23.7% decline in collaboration revenue to $6.9 million for the fiscal year. Despite these financial setbacks, the biopharmaceutical company is advancing a successful RINGSIDE trial with Varegacestat and plans a public offering. While the company exhibits strong liquidity and low debt, its high price-to-sales ratio, negative margins, and high volatility suggest potential risks for investors despite a generally positive analyst outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.